Guest guest Posted March 7, 2006 Report Share Posted March 7, 2006 BMS cancer drug gets FDA priority review PRINCETON, N.J., March 7 (UPI) -- Bristol-Myers Squibb said Tuesday the Food and Drug Administration gave priority review to cancer drug dasatinib. The company said the FDA will also review the new drug application for possible accelerated approval, meaning the treatment may be approved within six months, or by June 28, BMS said. BMS is seeking an indication for the compound for the treatment of chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia in adult patients with resistance or intolerance to prior therapy. Dasatinib is a second-generation protein tyrosine kinase inhibitor that some analysts predict could be as clinically and commercially successful as Novartis' Gleevec. However, Novartis has its own second-generation protein tyrosine kinase inhibitor in development. That treatment, AMN-107 -- which is in phase 2 studies -- may be able to treat CML cases that are resistant to Gleevec. Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.